Barclays Maintains Underweight on Definitive Healthcare, Lowers Price Target to $1

Barclays analyst Saket Kalia has maintained an Underweight rating on Definitive Healthcare (NASDAQ: DH) and has reduced the price target from $2.75 to $1. This adjustment reflects a more cautious outlook on the company's performance.